BioPharma Webinar Series
About this Series:
How can true spatial sequencing accelerate drug discovery and improve translation to the clinic? We curated a seminar series for the BioPharma community to share how ReadCoor’s technology and products deliver on the promise of this powerful technology. By participating, you will have the opportunity to connect with our team of experts and learn how our applications will enhance your research.
This seminar is free. Registration is required. It is available by invitation to the BioPharma community. To request an invitation, please email us at email@example.com.
Webinar Title: Fail Faster: True Spatial Sequencing for Rapid Single Assay PK/PD and Safety Profiling
Date: Wednesday, September 23, 2020
Time: 1:00 – 2:00 PM EDT
Access to the Webinar: This webinar is available by invitation. To request an invitation, please email us at firstname.lastname@example.org.
Webinar Abstract: In the biopharma industry, there is a need for rapid preclinical safety screening of novel molecular entities and therapeutic biologics to improve regulatory outcomes. Current gene therapies for example are hampered by deficits in assays to demonstrate specific delivery modalities, detect off-target toxicity, and co-localize the therapeutic molecules with resulting transcriptional and proteomic effects. In this webinar, we highlight how ReadCoor’s True Spatial Sequencing Platform can address this need by delivering high multiplexing spatial analysis and rapid screening of multi-faceted PK/PD profiling for novel gene therapies. The platform offers the combined massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging to simultaneously detect and visualize tens to thousands of RNA, DNA, proteins, and therapeutic molecules in situ. The capabilities of the platform go beyond conventional spatial profiling techniques by accurately capturing whole tissue microanatomy to reveal complex subcellular interactions including spatiotemporal dynamics, local immune response, targeted biomarkers, and gene expression in 3D.
Dr. Samuel A. Inverso will review:
- Key applications in immuno-oncology, neuroscience, and infectious disease
- Challenges in drug development and why there is a need for rapid, single-assay PK/PD, toxicity, and safety profiling
- How True Spatial Sequencing can be applied toward efficacy and safety profiling
- True Spatial Sequencing for retrospective clinical studies
Samuel A. Inverso, Ph.D.
VP, Global Partnerships
Samuel Inverso is an interdisciplinary leader with more than eighteen years of experience in technology and life sciences with a demonstrated history of success. Sam has formed and run cross-functional teams of molecular biologists, software engineers, and bioinformaticians in large scale multi-year projects. He has overseen more than $30 million in funding from pharma, universities, and the federal government. Sam excels at building and communicating strategic frameworks that bridge science and business objectives. At ReadCoor, he is engaged in corporate and business development. He manages collaborations with pharmaceutical and research institutes, including a Bill & Melinda Gates Foundation award and partnership with WAVE Life Sciences.
Prior to being a founding team member of ReadCoor, Sam was a Staff Engineer at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss, he contributed to analysis algorithms and bioinformatics for Fluorescent in situ Sequencing and is a co-author of the seminal 2014 Science paper. In addition, he was co-PI (with George Church) on a multi-million-dollar multi-year IARPA MICrONS project to use FISSEQ to map the neural circuits of a mouse brain at the synaptic level. The role included managing a large team of staff, postdocs, graduate students, and research assistants in interdisciplinary fields from molecular biology and engineering in a large consortium that included MIT, CSHL, and Columbia.
Sam received his Bachelor of Science and Master of Science in Computer Science from the Rochester Institute of Technology. He has a Ph.D. in Neuroscience from the Australian National University and Postdoctoral training in Alzheimer’s Disease at the Institut Pasteur.
Senior Director of Business Development
At ReadCoor, Mel oversees business development and strategic partnerships. Prior to joining the team at ReadCoor, Mel was a director of business development at WuXi NextCODE, a leader in disease-specific cohorts, AI solutions, and next-generation sequencing and analytic services. While at WuXi NextCODE, Mel managed large scale pharma partnerships focused on disease-specific patient cohorts. Before his tenure at WuXi NextCODE, Mel was the first business development manager and first commercial presence at Swift Biosciences. At Swift, Mel focused on the business development efforts for the next generation library prep business increasing revenue year over year for three years. Prior to Swift, Mel began his corporate career at Applied Biosystems (Acquired by LifeTech and then acquired by ThermoFisher), starting as a field applications scientist, making his way to various sales roles, gradually increasing responsibility and ending at a business development role at ThermoFisher’s Ion Torrent division. Before Applied Biosystems, Mel started at the Channing labs at Harvard School of Public Health. Mel was responsible for managing the day to day activity at the high throughput sequencing and genotyping facility. Mel received his Bachelor of Arts in Biology from Syracuse University.